Global health perspectives in prediabetes and diabetes prevention / Michael Bergman, editor.

Format:

Book

Contributor:

Bergman, Michael.

Language:

English

Subjects (All):

Diabetes--Prevention.

Diabetes.

Diabetes--Research.

Physical Description:

1 online resource (498 p.)

Place of Publication:

Singapore : World Scientific Publishing Co. Pte. Ltd., 2014.

Language Note:

English

Summary:

This comprehensive text is unique in its compilation of experiences in addressing the global diabetes epidemic and description of diverse worldwide prevention initiatives. Background chapters describe the diagnosis and definition of diabetes, the epidemiology, pathophysiology of prediabetes as well as clinical trial evidence for diabetes prevention and treatment. Furthermore, the critical role of government in formulating a global health agenda, policy perspectives for European initiatives, the importance of nutritional policies for diabetes prevention as well as the development of the necessa

Contents:

Contents; Preface; REFERENCES; Chapter 1: Diagnosis and Definition; 1. THE PAST HISTORY OF "GLUCOSE INTOLERANCE"; 2. THE MODERN ERA OF "PREDIABETES"; 2.1. Step 1; 2.2. Step 2; 2.3. Step 3; 2.4. Is HbA1c [5.7-6.4%] the Gold Standardfor Prediabetes?; 2.4.1. Pro; 2.4.2. Contra; 2.5. Is Prediabetes Really the First "Pathological" Threshold?; 3. CURRENT STATUS OF PREDIABETES; REFERENCES; Chapter 2: Epidemiology of Prediabetes; 1. BACKGROUND; 2. DEFINITIONS OF PREDIABETES; 2.1. Intermediate Hyperglycemia (IGT and IFG); 2.1.1. Impaired glucose tolerance; 2.1.2. Impaired fasting glucose

2.2. Glycated Hemoglobin (HbA1c)2.3. Risk Assessment Tools; 3. CONCLUSIONS; REFERENCES; Chapter 3: Pathophysiology of Prediabetes: Role of Lipotoxicity?; 1. INTRODUCTION; 2. β-CELL DYSFUNCTION AND INSULIN RESISTANCE; 3. ABDOMINAL OBESITY AND ECTOPIC FAT; 4. LIPOTOXICITY AND GLUCOTOXICITY; 5. MARKERS OF PROGRESSION FROM IGTTO TYPE 2 DIABETES; 6. CONCLUSIONS; REFEREN CES; Chapter 4: Primary Prevention Trials in Type 2 Diabetes; 1. INTRODUCTION; 1.1. Burden of Type 2 Diabetes; 2. PRIMARY PREVENTION OF DIABETES; 2.1. Risk Factors; 2.2. Types of Intervention; 3. INTERVENTION STRATEGIES

3.1. Lifestyle Modification (LSM)3.2. The China Da Qing Study10; 3.3. The Finnish Diabetes Prevention Study (DPS)11; 3.4. The Diabetes Prevention Program (DPP)12/The DPP Outcome Study (DPPOS)20; 4. STUDIES IN ASIAN POPULATIONS; 4.1. The Indian Diabetes Prevention Programs (IDPP)13; 4.2. Japanese Diabetes Prevention Studies; 4.3. Malmo Feasibility Study22; 5. RECENT DEVELOPMENTS; 5.1. Efficacy of Mobile Phone Messaging in Prevention of Diabetes24; 6. STUDIES USING PHARMACOLOGICAL AGENTS; 6.1. Metformin; 6.2. Alpha Glucosidase Inhibitors; 6.3. Thiazolidinediones (TZD)

6.4. The CAnadian Normoglycemia Outcomes Evaluation Trial316.5. Studies Using Other Drugs; 6.6. Antihypertensive Agents; 6.7. Safety of Pharmacological Agents; 7. MECHANISM OF ACTION OF INTERVENTION; 7.1. Cost-Effectiveness of Prevention Programs; 8. NATIONAL PROGRAMS; 9. CONCLUSIONS; REFERENCES; Chapter 5: Treatment of Prediabetes; 1. INTRODUCTION; 2. PATHOGENESIS OF T2DM; 2.1. Insulin Resistance; 2.2. Impaired β-Cell Function; 3. INSULIN RESISTANCE AND β-CELLFUNCTION IN IFG AND IGT; 4. INTERVENTION TO PREVENT THE PROGRESSION OF IGT TO T2DM; 4.1. Reversal of Insulin Resistance: Weight Loss

4.2. Reversal of Insulin Resistance: Pharmacologic Intervention4.2.1. Metformin; 4.2.2. Thiazolidinediones (TZDs); 4.3. Preservation of β-Cell Function; 4.3.1. Glucagon-like Peptide-1 (GLP-1) Analogs; 4.3.2. DPP-IV inhibitors; 4.4. α-Glucosidase Inhibitors; 5. IDENTIFICATION OF HIGH-RISK IGT INDIVIDUALS FOR PHARMACOLOGICAL THERAPY; 6. APPROACH TO THE PATIENT WITH PREDIABETES; 7. SUMMARY; 8. CONCLUSION; REFERENCES; Chapter 6: Diabetes Prevention and Nutrition Policies from a Global Perspective; 1. INTRODUCTION; 2. PRIMARY PREVENTION; 2.1. Addressing Overweight and Obesity

2.2. Increasing Physical Activity and Reducing Sedentary Behavior

Notes:

Description based upon print version of record.

Includes bibliographical references and index.

Description based on print version record.

ISBN:

981-4603-32-5